Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 77-81

  Guggino, Giuliana ^a,b   Giardina, AnnaRita ^a   Raimondo, Stefania ^b   Giardina, Giuseppina ^b   Sireci, Guido ^b   Dieli, Francesco ^b   Peralta, Marco ^a   Alessandro, Riccardo ^b   Triolo, Giovanni ^a   Ciccia, Francesco ^a  

^a Sezione di Reumatologia   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Early rheumatoid arthritis; Interleukin 6; T effector lymphpcytes; Tocilizumab

Indexed keywords

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894027889     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. KISHIMOTO T: The biology of interleukin-6. Blood 1989; 74: 1-10.
2. KISHIMOTO T: Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol 2005; 23: 1-21.
3. TAKEDA K, KAISHO T, YOSHIDA N, TAKEDA J, KISHIMOTO T, AKIRA S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998; 161: 4652-60.
4. DIENZ O, RINCON M: The effects of IL-6 on CD4 T cell responses. Clin Immunol 2009; 130: 27-33.
5. HU W, TROUTMAN TD, EDUKULLA R, PASARE C: Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. Immunity 2011; 35: 1010-22.
6. KIMURA A, KISHIMOTO T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-5.
7. BENUCCI M, MANFREDI M, SAVIOLA G, SARZI-PUTTINI P, ATZENI F: Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results. Clin Exp Rheumatol 2013; 31: 322-3.
8. YAZICI Y, CURTIS JR, INCE A et al.: Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol 2013; 31: 358-64.
9. SCHOELS MM, van der HEIJDE D, BREEDVELD FC et al.: Blocking the effects of interleukin- 6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72: 583-9.
10. FUJIMOTO M, SERADA S, MIHARA M et al.: Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-9.
11. SAMSON M, AUDIA S, JANIKASHVILI N et al.: Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499-503.
12. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
13. CICCIA F, GUGGINO G, RIZZO A et al.: Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 2012; 71: 295-301.
14. NIU Q, CAI B, HUANG ZC, SHI YY, WANG LL: Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012; 32: 2731-6.
15. TANAKA T, KISHIMOTO T: Immunotherapeutic implication of IL-6 blockade. Immunotherapy 2012; 4: 87-105.
16. ATREYA R, MUDTER J, FINOTTO S et al.: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
17. Van Den BRANDE JM, PEPPELENBOSCH MP, Van DEVENTER SJ: Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002; 973: 166-80.
18. VARADHACHARY AS, PERDOW SN, HU C, RAMANARAYANAN M, SALGAME P: Differential ability of T cell subsets to undergo activation- induced cell death. Proc Natl Acad Sci USA 1997; 94: 5778-83.
19. VARADHACHARY AS, PETER ME, PERDOW SN, KRAMMER PH, SALGAME P: Selective up-regulation of phosphatidylinositol 3'-kinase activity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex: a mechanism for Th2 resistance from Fas-mediated apoptosis. J Immunol 1999; 163: 4772-9.